<DOC>
	<DOC>NCT02335593</DOC>
	<brief_summary>The purpose of the study is to evaluate the effect of Zinc supplementation on health status of hemodialysis patients through measurement of the following before and after Zinc administration: Inflammatory markers, Oxidative stress markers and Anemia markers. Also, Evaluation of quality of life of hemodialysis patients before and after Zinc administration using Fatigue severity scale questionnaire.</brief_summary>
	<brief_title>Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<mesh_term>Zinc Sulfate</mesh_term>
	<criteria>Under regular hemodialysis for at least 6 months. Clinically stable condition as outpatients. Zincdeficient patients (plasma Zinc concentrations less than 80 mcg/dl). Patients taking any antioxidant supplements including vitamin E, Omega3 fatty acids, green tea preparations or immunosuppressive medications within 2 months prior to enrollment in the study. Patients receiving Al hydroxide phosphate binders. Hospitalization in the previous month before the onset of the trial, or having active infection. Patients with malabsorption diseases (e.g, Crohn's disease), liver diseases, cancers, mental retardation, dementia or psychiatric illness.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hemodialysis patients</keyword>
	<keyword>Zinc</keyword>
	<keyword>Anemia</keyword>
	<keyword>Oxidative stress</keyword>
</DOC>